Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VitaliThy trial of efgartigimod PH20 SC in Graves disease
jRCT2071260011Phase 3Recruiting
- Sponsor
- argenx
- Start
- Apr 2026
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in Graves' disease comparing efgartigimod PH20 SC with placebo PH20 SC (2 arms). Primary endpoint: Primary euthyroid off antithyroid drugs at week 24 (Part A). Started Apr 2026; status: recruiting.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
Graves' disease
Beyond the preview
Go deeper on jRCT2071260011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260011.